ACXP
Acurx Pharmaceuticals, Inc.3.5900
-0.1000-2.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.49MP/E (TTM)
-Basic EPS (TTM)
-8.18Dividend Yield
0%Recent Filings
8-K
Stockholders approve warrant exercise, share increase
Acurx Pharmaceuticals stockholders approved the issuance of shares underlying Series G-2 warrants at the September 16, 2025 special meeting, securing Nasdaq compliance under Listing Rule 5635(d) with 8.8 million votes in favor amid 9.8 million broker non-votes. They also greenlit increasing authorized common stock from 200 million to 250 million shares, passing 16.5 million to 2.5 million. This bolsters capital flexibility. Yet dilution looms for existing holders.
10-Q
Q2 FY2025 results
Acurx Pharmaceuticals narrowed its Q2 operating loss to $2.3M from $4.1M a year earlier, driven by R&D expenses dropping 71% y/y to $0.5M amid lighter Phase 2b activity, while G&A fell 24% to $1.7M on reduced share-based compensation. For the half-year, net loss improved 48% to $4.4M versus $8.5M, with operating cash burn easing to $3.7M from $5.9M, offset by $6.1M in fresh equity raises via direct offerings, warrant exercises, and an ELOC. Cash swelled to $6.1M, bolstering a lean liquidity posture with no debt. Yet Nasdaq compliance hangs in the balance.
8-K
Acurx enacts 1-for-20 split
Acurx Pharmaceuticals filed an amendment to its certificate of incorporation on July 31, 2025, implementing a 1-for-20 reverse stock split effective August 4, 2025, at 4:01 p.m. ET, with trading on a split-adjusted basis starting August 5 under ticker ACXP. This slashes outstanding shares from about 30.8 million to 1.5 million, aiming to boost the per-share price and meet Nasdaq's minimum bid requirement. Fractional shares get cashed out at the prior day's close. Compliance hangs on sustained price gains.
8-K
Acurx approves key governance measures
Acurx Pharmaceuticals held its annual meeting on July 17, 2025, where shareholders elected Carl V. Sailer and Thomas Harrison as Class I directors until 2028. They ratified CohnReznick LLP as auditors for 2025 and approved a reverse stock split at a 1:10 to 1:30 ratio, at board discretion. Shareholders also greenlit warrant exercises with H.C. Wainwright and equity issuances to Lincoln Park to meet Nasdaq rules, plus boosting the 2021 Plan shares to 2,677,448. This bolsters capital access amid liquidity needs.
8-K
Warrant exercise yields $2.3M net
Acurx Pharmaceuticals secured $2.67 million in gross proceeds from a holder exercising 4,445,435 existing warrants at a reduced $0.60 per share, issuing new G-1 and G-2 warrants for 8,890,870 shares at $0.425 each in return. Net proceeds of $2.3 million will fund working capital amid cash constraints. Closing hits June 20. Yet dilution looms large.
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
ANNX
Annexon, Inc.
4.80-0.11
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RXRX
Recursion Pharmaceuticals, Inc.
4.20+0.00
VINC
Vincerx Pharma, Inc.
0.01+0.00
XCUR
Exicure, Inc.
6.06+0.33